Ren Ken Keyong 4
4 · CASI Pharmaceuticals, Inc. · Filed Dec 6, 2018
Insider Transaction Report
Form 4
Ren Ken Keyong
Chief Executive Officer
Transactions
- Award
Stock Options (Right to Buy)
2018-12-03+720,000→ 720,000 totalExercise: $0.99From: 2018-12-03Exp: 2027-08-14→ Common Stock (720,000 underlying)
Footnotes (1)
- [F1]On August 14, 2017, the reporting person was granted an option to purchase 720,000 shares of common stock that vest upon achievement of certain performance based conditions. The performance based condition was satisfied on December 3, 2018, resulting in vesting of the option.